• Link to Facebook
  • Link to Instagram
  • Link to X
  • Link to Youtube
  • Link to LinkedIn
  • Link to TikTok
  • About
  • Become a Member
  • Update Your Information
  • Contact Us
  • SRNA Blog
  • Merch
SRNA Menu
  • Newly Diagnosed
  • Disease Information
      • Rare Neuroimmune Disorders
          • What are Rare Neuroimmune Disorders?
          • Mechanisms of Disease
          • Differential Diagnoses
          • Diagnosis
          • Acute Treatments
      • Acute Disseminated Encephalomyelitis
          • What is ADEM?
          • Epidemiology
          • Signs & Symptoms
          • Diagnosis
          • Acute Treatments
          • Prognosis & Management
          • Long-Term Care
      • Acute Flaccid Myelitis
          • What is AFM?
          • Epidemiology
          • Signs & Symptoms
          • Diagnosis
          • Acute Treatments
          • Prognosis
          • Rehabilitation & Symptom Management
      • MOG Antibody Disease
          • What is MOGAD?
          • Epidemiology
          • Signs & Symptoms
          • Diagnosis
          • Acute Treatments
          • Prognosis & Management
          • Long-Term Care
      • Neuromyelitis Optica Spectrum Disorder
          • What is NMOSD?
          • Epidemiology
          • Signs & Symptoms
          • Diagnosis
          • Acute Treatments
          • Prognosis & Management
          • Long-Term Care
      • Optic Neuritis
          • What is ON?
          • Epidemiology
          • Signs & Symptoms
          • Diagnosis
          • Acute Treatments
          • Prognosis & Management
      • Transverse Myelitis
          • What is TM?
          • Epidemiology
          • Signs & Symptoms
          • Diagnosis
          • Acute Treatments
          • Prognosis & Management
          • Long-Term Care
  • Programs & Services
      • Individuals Diagnosed & Caregivers
        • Programs
            • Coaching Series on Relationships and Emotional Well-Being
            • Quality of Life Family Camp
            • Rare Neuroimmune Disorders Symposium
        • Education Resources
            • Online Learning
            • Resource Library
            • SRNA Magazine
            • Ask the Expert Podcast Series
            • ABCs of NMOSD Podcast Series
            • ADEM Academy Podcast Series
            • Community Meets Clinic
            • NMOSD Drugs
        • Support Resources
            • Myelitis Helpline
            • Peer Connect Program
            • Visit a Center of Excellence
            • Support Group Network
            • Smart Patients Online Health Community
            • Medical Professional Network
      • Researchers & Healthcare Professionals
        • Programs
            • James T. Lubin Fellowship
            • Become a Center of Excellence
            • Continuing Medical Education
            • AFM Physician Support Portal
        • Resources
            • Medical Professional Resource Center
            • Neurology Live
            • Connect With SRNA and Request Materials
        • Healthcare Professional Digest
            • 2023 | Issue 1
            • 2023 | Issue 2
            • 2024 | Issue 1
            • 2024 | Issue 2
  • Research
      • Participate in Research
          • SRNA Registry
          • Clinical Studies & Trials
      • SRNA Funded Research
          • The Pauline H. Siegel Eclipse Fund for Research
          • Supported Centers of Excellence
          • Academic Grants
          • Funded Research Publications
      • Research Updates
          • 2022-2023 Research Updates
          • 2021 Research Updates
          • 2020 Research Updates
          • 2019 Research Updates
          • 2018 Research Updates
  • Events
    • What’s New – April/May Edition
    • SRNA + CanDo Coaching Series
    • 2025 Camp
    • 2025 Regional RNDS
    • Walk-Run-N-Rolls
    • Support Group Meetings
    • All Upcoming Events
  • Get Involved
    • Donate
    • Volunteer
    • Share your Story
    • Become a Member
    • Join our Registry
    • Careers
  • Donate
    • Give Once
    • Give Monthly
    • Give in Someone’s Honor
    • Fundraise
    • International Donations
  • Menu Menu


Menu

  • Improving Diagnoses

  • Understanding Causation

  • Restoring Function

  • SRNA James T. Lubin Fellows

  • SRNA-Led Research

  • Research-related resources

2019 Research Updates

2019 was another exciting year for research on rare neuroimmune disorders. We know how important research is for improving the quality of life of our community and it remains a top commitment for us as an organization.

We do this through The Pauline H. Siegel Eclipse Fund for research. This fund drives critical research priorities including improving diagnosis, understanding causation, investigating novel therapies, and restoring function.

We share some of the research advances here with you.

Improving Diagnoses

SRNA maintains our commitment to advancing the scientific understanding of ADEM, AFM, MOGAD, NMOSD, ON, and TM to help improve diagnostic speed and accuracy. Some of this SRNA-supported research was presented at the American Academy of Neurology Annual Meeting, which was held from May 4th-10th in Philadelphia, PA.

Dr. Olwen Murphy, a former James T. Lubin Fellow, and a team at The Johns Hopkins Hospital presented research on sarcoidosis-related myelitis. The research was a retrospective study of patients diagnosed with sarcoidosis-related myelitis at the Johns Hopkins Transverse Myelitis Center. The goal of the study was to identify characteristic clinical, imaging and CSF features of sarcoidosis-related myelitis. They found that distinct imaging patterns occur in sarcoidosis-related myelitis and recognition of these features may aid in coming to a correct diagnosis. Most of the patients in the study had a long symptom evolution (81%), meaning it took more than three weeks from symptom onset to when symptoms were at their worst. Most had sensory symptoms (87%) and motor symptoms (53%). Enhancement patterns suggest that the blood-spinal-cord barrier may play a role in the development of sarcoidosis-related myelitis lesions. Dr. Murphy and colleagues also presented a case report on a 68-year-old man who presented with a 2-year history of severe muscle spasms in the lower back and pelvic region. The patient was ultimately referred to their clinic for evaluation of “treatment-resistant” stiff person syndrome after baclofen and benzodiazepines had no clinical effect. He was correctly diagnosed with an anterior disco-osteo-arterial conflict and underwent surgery to correct the problem. Six months post-surgery he reported marked improvement in his symptoms and increased exercise tolerance. The findings from these studies provide additional information about these diagnoses, which are important for ensuring people receive an accurate diagnosis.

Dr. Jonathan Galli, another James T. Lubin Fellow, worked with Dr. Clardy on another research study about stiff person syndrome. The goal was to describe epidemiological characteristics, antibody status, and treatment outcomes of stiff person syndrome patients within University of Utah Health. Stiff person syndrome (SPS) is an autoimmune disease that classically causes severe muscle rigidity and spasms. They identified 31 patients with stiff person syndrome. Patients were predominantly female (78%). Some of their cohort had co-existing autoimmune diseases (63%) and malignancy (13%). Diazepam and baclofen was effective in a majority of patients. IVIg was the most commonly utilized immunotherapy (used in 69% of patients) with benefit demonstrated in 41% of patients who received this treatment. Dr. Galli and colleagues also presented a case series with the goal to describe atypical epilepsy presentations in patients with common variable immunodeficiency (CVID) within the University of Utah Healthcare system. Patients with CVID are at increased risk of infection, malignancy, and autoimmune disease. They presented a case series of 5 patients with CVID and co-existing epilepsy. All patients had atypical seizure symptoms including behavioral arrest, alterations in consciousness, and/or amnestic episodes. Most of the patients had improvement with antiepileptic therapy.

Dr. Cynthia Wang, another former James T. Lubin Fellow, and colleagues presented a case report of a 6-year-old boy with new-onset seizures and altered mental status associated with multifocal right hemispheric lesions resulting from primary CNS vasculitis. Primary CNS vasculitis is a rare vascular inflammatory brain disease. The child was treated with cyclophosphamide with gradual improvement in cerebral edema, and he also underwent cranioplasty four weeks after hemicraniectomy. He improved significantly over one month in inpatient rehabilitation and he regained the ability to ambulate independently. The researchers note that this case demonstrates an unusual presentation of this condition in a child.

Understanding causation

In 2017, Dr. Michael Levy announced the discovery of a mutation in the VPS37A gene found in 3 people with acute idiopathic transverse myelitis (ITM): 2 sisters from a Polish origin and 1 unrelated Scotch-Irish woman. Given the rarity of this mutation in the world population and in the animal kingdom in general, he proposed to screen additional ITM patients for mutations in this gene. VPS37A, which stands for Vacuolar Protein Sorting-associated protein 37A, makes a protein that is important for shuttling proteins around the cell. The mechanism for how this gene is involved in the development of ITM is active area of research in Dr. Levy’s lab. While his lab worked to understand the scientific basis of the mutation in exon 6 of this gene and its role in the immune surveillance of the spinal cord, they expanded their efforts to look at the rest of the VPS37A gene.

They screened the 89 original cases from samples already banked in the lab, and also recruited an additional 45 samples remotely from sources such as Facebook and the Siegel Rare Neuroimmune Association. The VPS37A gene contains 12 exons – regions of genetic sequence that encode the protein. Exon 6 was the location of the known mutation. They then looked at the rest of the 11 exons for additional mutations.

They found 5 additional patients with VPS37A mutations, 3 of them in exon 7 and 2 of them in exon 5. All of these mutations, including the original mutation in exon 6, can potentially compromise protein function. Additional studies of the VPS37A gene in mice will shed light on the role of this protein in TM. Similar to the mutation in exon 6, the mutation discovered in exon 5 is exceedingly rare in the world. More notably, the mutation in exon 7 among 3 ITM patients was not previously reported in any human being. It is also notable that exon 5, 6 and 7 are very closely opposed to each other within the VPS37A gene. These findings suggest that these mutations in this part of the VPS37A gene predispose to ITM.

Restoring function

Once damage had been done to the brain, spinal cord, or optic nerve, it is important to try to find therapies that can reverse all or part of this damage and help restore function. SRNA is incredibly excited to be working with UT Southwestern Medical Center and Q Therapeutics to study the safety and efficacy of implanting cells that produce myelin into the spinal cord. It is the first study of its kind in transverse myelitis. For more information on the study click here.

We have received FDA clearance to proceed with this phase one trial in paralyzed TM patients. The trial currently plans to enroll nine patients for the surgical implantation of Q Cells. This is a safety study with many regulatory requirements, including a requirement focused on training the surgical team to perform the procedure with novel technology. The UT Southwestern team worked during the year to get complete licensing and credentialing requirements for the team, with hopes to start the first surgery in 2020. Then, the COVID-19 pandemic began, halting plans for first enrollment and surgery. Research is expected to reopen at UT Southwestern in 2020.

SRNA James T. Lubin Fellows

In addition to some of the research described above, we remain committed to funding Fellowships to train clinician-scientists in rare neuroimmune disorders. In 2019, SRNA supported three Fellows and their research projects.

Dr. Olwen Murphy, Johns Hopkins University

Dr. Murphy’s research was on predicting outcomes after a diagnosis of transverse myelitis using current imaging techniques and spinal fluid analysis. The goal of the research project was to identify patterns or biomarkers that can be used in day-to-day clinical practice to identify benefits from therapies and help make better decisions about care.

Dr. Kyle Blackburn, University of Texas Southwestern

During his fellowship, Dr. Blackburn launched a study that collects patient-reported outcome measures on adult and pediatric patients with transverse myelitis. The study aims to assess current outcomes in transverse myelitis and to inform the development of outcome measures for future clinical trials.

Dr. Jonathan Galli, University of Utah

As part of his fellowship training, Dr. Blackburn conducted research to look for biomarkers in individuals with NMOSD. He investigated whether individuals have aquaporin-­4 (AQP­4) autoantibodies prior to their symptom onset of NMOSD, and also look for other inflammatory biomarkers. The goal of the study is to help us understand how biomarkers occur over the course of the disorder, which will hopefully help identify predictors of disease development, and ultimately therapeutic targets.

SRNA-Led Research

SRNA also launched a study about experiences with vaccinations after a rare neuroimmune disorder diagnosis. The goal of the study was to understand and learn from our member community about their experiences with receiving vaccinations before and after a rare neuroimmune disorder diagnosis, with a focus on their experiences after diagnosis. The study involved participation in a survey administered using Surveymonkey and through postal mail. Respondents who reported that they experienced a repeat inflammatory attack within 30 days of receiving a vaccine were further requested to participate in an interviewer-administered questionnaire over the phone. We were interested in researching the following questions:

  1. What percentage of individuals with rare neuroimmune disorders have received vaccinations after their diagnosis
  2. What has been their physician’s advice regarding vaccinations?
  3. Of those who received vaccinations, what vaccinations did they receive, and did they experience any complications, including a new inflammatory attack 30 days or less after a vaccination?

We randomly selected 600 people from our membership database and sent them the survey. Ten of these individuals were deceased, five had no valid contact information, two ended up getting a different diagnosis, three were not in the US, nine had a symptom onset less than a year before, and all of these individuals were excluded. 220 participants fully completed the survey. Data analysis is ongoing, with results expected in 2020.

SRNA also continues to collect data for our patient Registry. The purpose of this registry is to help advance research about rare neuroimmune disorders, collaborate with researchers from around the world, and identify participants for clinical trials. In 2019, 256 people participated in the registry.

get to know us

careers

meet our staff

meet our partners

see financials

contact us

connect

become a member

find a local support group

find a medical professional

our community in the news

memorials

resources

access our resource library

myelitis helpline

ask the expert podcast series

get involved

volunteer

start a campaign

start a walk in your city

start a support group



DONATE


© 2025 Siegel Rare Neuroimmune Association - US 501 (c)(3) public charity, EIN 91-1780467 - All Rights Reserved. - Terms of Use - Privacy Policy
  • Link to Facebook
  • Link to Instagram
  • Link to X
  • Link to Youtube
  • Link to LinkedIn
  • Link to TikTok
Scroll to top Scroll to top Scroll to top

Have a cookie! 🍪 This site uses cookies. We use cookies for a number of reasons, such as keeping SRNA's website reliable and secure, and providing social media features, and to analyze how our website is used. By continuing to browse the site, you are agreeing to our use of cookies.

AcceptDenyLearn more

Cookie and Privacy Settings



How we use cookies

We may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.

Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.

Essential Website Cookies

These cookies are strictly necessary to provide you with services available through our website and to use some of its features.

Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.

We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.

We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.

Other external services

We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.

Google Webfont Settings:

Google Map Settings:

Google reCaptcha Settings:

Vimeo and Youtube video embeds:

Privacy Policy

You can read about our cookies and privacy settings in detail on our Privacy Policy Page.

Privacy Policy
Accept settingsHide notification only
  • Share
  • Tweet
  • Email
  • Print